



Public Declaration of Interests and Confidentiality Undertaking of European Medicines Agency (EMA)

SCIENTIFIC COMMITTEE MEMBERS AND EXPERTS

I, Jenny-Maria Jönsson

Organisation/Company: N/A

Country: Sweden

Declare on my honour that, to the best of my knowledge, the only direct or indirect interests I have in the pharmaceutical industry are those listed below:

1.1 Employment

No interest declared

1.2 Consultancy

Time Period	Start Date	End Date	Name of pharmaceutical company	Type	Product name	Therapeutic indication	General role / Area of activity
Past	01-04-2022	01-04-2022	MSD/Eisai	Individual product related	Keytruda (pembrolizumab) and Lenvima (le	Endometrial cancer	null
Past	01-04-2021	01-04-2021	Eisai	Individual product related	Keytruda (pembrolizumab) and Lenvima (le	Endometrial cancer	null

1.3 Strategic advisory role

No interest declared

1.4 Financial interests

No interest declared

1.5 Principal investigator

No interest declared

1.6 Investigator

Time Period	Start Date	End Date	Name of pharmaceutical company	Product Name	Therapeutic indication
Past	01-04-2022	01-09-2022	MSD	Keytruda (pembrolizumab)	Advanced and recurrent endometrial cancer
Past	01-09-2019	01-05-2022	Clovis	Rubraca (rucaparib)	Advanced and recurrent ovarian cancer, m
Past	01-06-2018	01-08-2022	Astra Zeneca	Lynparza (olaparib)	Recurrent ovarian cancer, maintenance tr

Past	01-01-2020	01-08-2022	Roche	Tecentriq (atezolizumab)	Metastatic cervical cancer
Past	01-10-2021	01-03-2022	GSK	Jemperli (dostarlimab)	Advanced and recurrent endometrial cancer
Past	01-01-2014	01-04-2021	GSK	Zejula (niraparib)	Recurrent ovarian cancer, maintenance treatment
Past	01-01-2014	01-08-2022	Roche	Avastin (bevacizumab)	Metastatic and cervical and ovarian cancer
Past	01-09-2019	01-05-2022	BMS	Opdivo (nivolumab)	Advanced and recurrent ovarian cancer

1.7 Grant / Funding to organisation /institution

No interest declared

1.8 Close family member interest

No interest declared

1.9 Repurposing of a medicinal product

No interest declared

1.10 Any other interests or facts

Sub_investigator in an academic trial on advanced endometrial cancer (Fandango trial). Investigating the potential role of Ofev/Vargatef (nintedanib, provided by Boeringer Ingelheim) in the treatment of endometrial cancer August 2017 _ December 2019. Personal research grant from Roche in 2012. Roche was involved in electing grant recipient, but was not involved in the pre_clinical studies performed using the research grant. The studies did not comprise any specific medicinal products. Current staff member at Lund University, Sweden (pre_clinical ovarian and endometrial cancer research)

1.11 Committee for Advanced Therapies (CAT) member or alternate

Not a CAT member or alternate

2.1 Employment

No interest declared

2.2 Consultancy

No interest declared

2.3 Strategic advisory role

No interest declared

2.4 Financial interests

No interest declared

2.5 Principal investigator

No interest declared

2.6 Investigator

No interest declared

2.7 Grant / Funding to organisation /institution

No interest declared

2.8 Close family member interest

No interest declared

2.9 Any other interests or facts

No interest declared

CONFIDENTIALITY UNDERTAKING

In view of the following definitions:

"EMA Activities" encompass any meeting (including meeting preparation and follow-up, associated discussion or any other related activity) of the European Medicines Agency's Management Board, Committees, Working Parties, Expert Groups, or any other such meeting; work as an expert on assessments; work as an expert on guidance development.

"Confidential Information" means all information, facts, data and any other matters of which I acquire knowledge, either directly or indirectly, as a result of my EMA Activities.

"Confidential Documents" mean all drafts, preparatory information, documents and any other material, together with any information contained therein, to which I have access, either directly or indirectly, as a result of my participation in EMA Activities. Furthermore, any records or notes made by me relating to Confidential Information or Confidential Documents shall be treated as Confidential Documents.

I understand that I may be invited to participate either directly or indirectly in certain EMA activities and hereby undertake:

- To treat all Confidential Information and Confidential Documents under conditions of strict confidentiality as long as the information or document has not been made public/is not in the public domain.

- Not to disclose (or authorise any other person to disclose) in any way to any third party ¹ any Confidential Information or Confidential Document.
- Not to use (or authorise any other person to use) any Confidential Information or Confidential Document other than for the purposes of my work in connection with EMA activities.
- To dispose of Confidential Documents as confidential material as soon as I have no further use for them.
- When expressing views to indicate clearly that the views are my own if acting in my own capacity or those of the EMA, Management Board, Committee, Working Party, Expert Group or other group if acting on behalf of that group.
- Not to disclose any commercially confidential information.

This undertaking shall not be limited in time, but shall not apply to any document or information that I can reasonably prove was known to me before the date of this undertaking or which becomes public knowledge other than as a result of a breach of any of the above undertakings.

I confirm the information declared on this form is accurate and complete to the best of my knowledge and I acknowledge that my information will be stored electronically and published on the EMA website.

1. Third party does not include employees of the National Competent Authorities who either have employment contracts that provide confidentiality obligations or are encompassed by confidentiality obligations under national legislation on professional secrecy.

Full Name:	Jenny-Maria Jönsson
Date:	2023-03-31

For definitions of activities etc, refer to the policy on handling of competing interests.